X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: $182.4 million Upfront Cash: $78.5 million
Deal Type: Acquisition June 09, 2022
Details:
Opportunity for Eagle’s highly skilled hospital-based salesforce to integrate and promote BYFAVO and BARHEMSYS and to leverage longstanding relationships to realize the full potential of these assets.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: $182.4 million Upfront Cash: $78.5 million
Deal Type: Acquisition March 28, 2022
Details:
Barhemsys® is an intravenous formulation of amisulpride, a selective dopamine antagonist. It is approved in the US for treatment and prophylaxis of PONV, alone and in combination with other antiemetics.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programs.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $23.5 million Upfront Cash: Undisclosed
Deal Type: Financing February 18, 2021
Details:
BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia.
Lead Product(s): Remimazolam Besylate
Therapeutic Area: Neurology Product Name: Byfavo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
Under the Investment Agreement, Cosmo would have become eligible to receive a €5 million payment from the Company payable in new ordinary shares in the Company conditional upon the first commercial sale of the BYFAVO™ product in the United States.
Lead Product(s): Remimazolam Besylate
Therapeutic Area: Neurology Product Name: Byfavo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cosmo Pharmaceuticals
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Agreement December 15, 2020
Details:
The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 09, 2020
Details:
US DEA has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs.
Lead Product(s): Remimazolam Besylate
Therapeutic Area: Neurology Product Name: Byfavo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Acacia Pharma has been assigned the US license to BYFAVO™ (remimazolam) for injection by Cosmo Pharmaceuticals NV. BYFAVO for injection is a very rapid onset/offset intravenous benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less.
Lead Product(s): Remimazolam Besylate
Therapeutic Area: Neurology Product Name: Byfavo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cosmo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
